 AUSTIN, Texas, July 26, 2021 GLOBE NEWSWIRE -- Lumos Pharma, Inc. NASDAQ:LUMO, a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D., Ph.D., accepted his appointment to the Companys Clinical Scientific Advisory Board CSAB effective July 15, 2021. Dr. Bach joins the Companys accomplished advisory board comprised of noted pediatric endocrinologists, Peter Clayton, M.D., Ph.D.; Reiko Horikawa, M.D., Ph.D.; George Werther, M.D., Ph.D.; and Chairman, Ron Rosenfeld, M.D. 